Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce,R. Gregory Bociek,Ahmed Sawas,Paolo Caimi,Edward Agura,Jeffrey Matous,Stephen M. Ansell,Howland E. Crosswell,Miguel Islas-Ohlmayer,Caroline Behler,Eric C. Cheung,Andres Forero-Torres,Julie M. Vose,Owen A. O'Connor,Neil C Josephson,Yinghui Wang,Ranjana H. Advani +16 more
Reads0
Chats0
TLDR
Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients is determined byThe allele ratio is defined as the sum of the following: A.J.F., Wilson, R.K.Abstract:
F., Wilson, R.K., Ley, T.J. & Ding, L. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 20, 1472–1478. Yuan, X.Q., Chen, P., Du, Y.X., Zhu, K.W., Zhang, D.Y., Yan, H., Liu, H., Liu, Y.L., Cao, S., Zhou, G., Zeng, H., Chen, S.P., Zhao, X.L., Yang, J., Zeng, W.J. & Chen, X.P. (2019) Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients. Journal of Translational Medicine, 17, 220.read more
Citations
More filters
Journal ArticleDOI
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Ryan C. Lynch,Ryan C. Lynch,Ryan D. Cassaday,Ryan D. Cassaday,Stephen D. Smith,Stephen D. Smith,Jonathan R. Fromm,Andrew J. Cowan,Andrew J. Cowan,Edus H. Warren,Edus H. Warren,Mazyar Shadman,Mazyar Shadman,Andrei R. Shustov,Andrei R. Shustov,Brian G. Till,Brian G. Till,Chaitra S. Ujjani,Chaitra S. Ujjani,Edward N. Libby,Edward N. Libby,Mary Philip,Hilary Coye,Christen N. Martino,Sandra L Bhark,Karolyn Morris,Heather Rasmussen,Sanaz Behnia,Jenna M. Voutsinas,Ajay K. Gopal,Ajay K. Gopal +30 more
TL;DR: In this paper, the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma was investigated.
Journal ArticleDOI
LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
Scott Moerdler,Michelle Ewart,Debra L. Friedman,Kara M. Kelly,Kara M. Kelly,Qinglin Pei,Mou Peng,Mou Peng,Xingxing Zang,Peter D. Cole +9 more
TL;DR: Patient tumor samples from Children’s Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed and there was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression.
Journal ArticleDOI
Bendamustine: A review of pharmacology, clinical use and immunological effects
TL;DR: The current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and toxicity was summarized, and its immune-modulating effects that have not been fully elucidated so far are emphasized to encourage further investigations of this unique drug.
Journal ArticleDOI
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
Annabel McMillan,Aideen Therese O'Neill,William Townsend,Jonathan Lambert,Andres Virchis,Raakhee Shah,Leon Menezes,Paul Humphries,Kirsten Von Both,Victoria Grandage,Ben Carpenter,Rachael Hough,Kirit M. Ardeshna,Stephen Daw +13 more
Journal ArticleDOI
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
Luciana Vinti,Daria Pagliara,Salvatore Buffardi,Valentina Di Ruscio,Francesca Stocchi,Elena Mariggiò,Rosanna Parasole,Antonia Di Matteo,Fara Petruzziello,Valeria Paganelli,Rita De Vito,Francesca Del Bufalo,Luisa Strocchio,Francesco Locatelli +13 more
TL;DR: Brentuximab vedotin in combination with bendamustine may represent a suitable salvage therapy in patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome.
References
More filters
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro,Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Journal ArticleDOI
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz,Auayporn Nademanee,Tamas Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick J. Stiff,Alessandro M. Gianni,Angelo Michele Carella,Dzhelil Osmanov,Veronika Bachanova,John W. Sweetenham,Anna Sureda,Dirk Huebner,Eric L. Sievers,Andy Chi,Emily K. Larsen,Naomi N. H. Hunder,Jan Walewski +19 more
TL;DR: Early consolidation with brentuximab vedotin after autologous stem-cell transplantation improved progression-free survival in patients with Hodgkin's lymphoma with risk factors for relapse or progression after transplantation.
Journal ArticleDOI
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz,Matthew J. Matasar,Andrew D. Zelenetz,Stephen D. Nimer,John F. Gerecitano,Paul A. Hamlin,Steven M. Horwitz,Alison J. Moskowitz,Ariela Noy,Lia Palomba,Miguel-Angel Perales,Carol S. Portlock,David J. Straus,Jocelyn C. Maragulia,Heiko Schöder,Joachim Yahalom +15 more
TL;DR: Evidence is provided that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT, and a risk-adapted approach to improve PFS after high-dose radio-chemotherapy (HDT) and ASCT is used.
Related Papers (5)
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma
Sagun D. Goyal,Nancy L. Bartlett +1 more